Compare Marsh & McLennan Companies, Inc. (MRSH) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs BIO-TECHNE Corp — how do they compare? Marsh & McLennan Companies, Inc. trades at $191.32 (market cap $91.05B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 8.1× BIO-TECHNE Corp's market cap, and Marsh & McLennan Companies, Inc. pays the higher dividend (2.08%). Which is the better fit depends on your goals.
| MRSH | TECH | |
|---|---|---|
Market Cap | $91.05B | $11.24B |
Sector | Financials | Health |
52-Week High | $211.21 | $72.29 |
52-Week Low | $157.32 | $43.31 |
Enterprise Value | $111.73B | $11.32B |
Dividend Yield | 2.08% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marsh & McLennan (MRSH) trades at $191.65, down 0.85% on the day, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.96 exceeding expectations. Revenue growth remains solid at 6% in Q2 2026, while the company maintains healthy profitability with a 14.24% net income margin. Recent acquisitions and AI investments highlight strategic growth initiatives.
The outlook for MRSH is positive, supported by earnings momentum and a consensus price target of $202.89 offering potential upside. However, margin pressure from rising expenses and soft P&C pricing present near-term risks. Institutional activity shows mixed sentiment, with some firms increasing stakes while others reduce holdings.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
